



# fosaprepitant 150mg powder for solution for infusion (Ivemend)

MSD UK Ltd

05 October 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**fosaprepitant (Ivemend 150mg<sup>®</sup>)** is accepted for use within NHSScotland.

**Indication under review:** prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years. Fosaprepitant is given as part of a combination therapy.

SMC has previously accepted fosaprepitant as part of combination therapy for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults (678/11).

SMC has previously accepted aprepitant for use as part of combination therapy for the prevention of nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to 17 years (1252/17 and 1241/17 respectively). Intravenous fosaprepitant is a pro-drug of oral aprepitant and it offers an alternative with limited budget impact.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 16 August 2018.*

**Chairman  
Scottish Medicines Consortium**